Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in IgA Nephropathy
NCT05065970Phase 2Completed
- Sponsor
- Biogen
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of felzartamab in IgA nephropathy (IgAN) (5 arms), sponsored by Biogen. Primary endpoint: Urine Protein to Creatinine Ratio at 9 months. Started Aug 2021; status: completed.
02
Drugs
felzartamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05065970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065970.